Invex in 2020 stated that Bydureon's 3 hour release profile...

Invex in 2020 stated that Bydureon's 3 hour release profile wasn't optimised for IIH. But today, Invex has decided to use Peptron's sustained release exenatide despite it also having a 3 hour peak effect profile.

What i've concluded is that the company made a throw away comment in their 2020 presentation to help explain to the market its planned formulation efforts.

In truth, it seems that Bydureon works for IIH just like Byetta, since they're both made out of Exenatide. The difference is that Invex needs to have a unique formulation so that people don't simply just use off-label Byetta/Bydureon.

Fortunately, Peptron had a unique formulation with the requisite regulatory data, so instead of reinventing the wheel they've jumped onboard with Peptron's sustained release formulation of exenatide.

On reflection, it's actually a masterstroke.